News Contrasting fortunes for Duchenne rivals, as PTC fails and S... Two rivals in the emerging Duchenne muscular dystrophy (DMD) therapy area have experienced contrasting fortunes this week.
News PTC Therapeutics fails to convince FDA panel about DMD drug FDA advisers have voted against approval for PTC Therapeutics’ Duchenne drug Translarna because of doubts about its efficacy.
News FDA reviewers slam PTC's Duchenne drug ahead of meeting FDA staff not persuaded by patchy clinical trial evidence for Translarna.
News Sarepta announces Allergan veteran as next CEO Sarepta has announced former Allergan president Doug Ingram will be its new CEO.
News UK patients gain early access to Duchenne drug Patients to get Santhera's Raxone under EAMS scheme.
R&D Driving the drug discovery pipeline: The value of organ-on-a... In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostrzewski, CSO at CN Bio, about single organ-on-a-chip technology.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
